How patients are responding to elinzanetant, with Genevieve Neal-Perry, MD, PhD

On October 24, 2025, the FDA approved elinzanetant 60 mg capsules (Lynkuet; Bayer) for the treatment of moderate to severe hot flashes due to menopause, ushering a significant advancement for women’s health.¹

Approved based on the the phase 3 OASIS-3 trial where participants receiving elinzanetant reported an over 73% reduction in symptom frequency and severity by week 12, elinzanetant was a welcomed addition for treating vasomotor symptoms.

Since the approval, how have patients been responding to elinzanetant? In the video above, Genevieve Neal-Perry, MD, PhD, of the University of North Carolina School of Medicine, Chapel Hill, answers that question and many more in the above interview from the 2026 American College of Obstetricians & Gynecologists (ACOG) Annual Clinical & Scientific Meeting.²

References:

1. Krewson C. FDA approves elinzanetant (Lynkuet) for vasomotor menopausal symptoms. Contemporary OB/GYN. Published October 24, 2025. Accessed May 1, 2026. https://www.contemporaryobgyn.net/view/fda-approves-elinzanetant-lynkuet-for-vasomotor-menopausal-symptoms
2. ACOG. Contemporary OB/GYN. Accessed May 1, 2026. https://www.contemporaryobgyn.net/conferences/acog